I. Ieiri

发表

Statin Inhibits the Expression of Secretory Phospholipase A2 and Subsequent Monocyte Chemoattractant Protein-1 in Human Endothelial Cells

T. Kitazono, S. Ohdo, K. Sonoki, 2014, Journal of cardiovascular pharmacology.

Functional Analysis of SNPs Variants of BCRP/ABCG2

Y. Sugiyama, S. Ozawa, J. Sawada, 2004, Pharmaceutical Research.

Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice

T. Kinoshita, S. Higuchi, H. To, 2009, The Journal of pharmacy and pharmacology.

Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats.

H. Sasaki, S. Higuchi, Kanoko Egashira, 2012, Drug metabolism and pharmacokinetics.

Circadian Disruption Accelerates Tumor Growth and Angio/Stromagenesis through a Wnt Signaling Pathway

Y. Sasaguri, H. Izumi, K. Kohno, 2010, PloS one.

Multiple gene polymorphisms and warfarin sensitivity

H. Takane, I. Ieiri, E. Shikata, 2006, European Journal of Clinical Pharmacology.

Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy

E. Shimizu, N. Burioka, M. Miyata, 2006, Journal of Human Genetics.

Epigenetic regulation of drug transporter expression in human tissues

Toshihiro Tanaka, I. Ieiri, Takeshi Hirota, 2017, Expert opinion on drug metabolism & toxicology.

Mechanism of the 24-hour rhythm of tumor necrosis factor-alpha formed by onset of rheumatoid arthritis

H. To, I. Ieiri, Hiromichi Yoshimatsu, 2014, Chronobiology international.

Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy

S. Higuchi, H. Takane, I. Ieiri, 2006, Expert opinion on drug metabolism & toxicology.

Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).

Y. Sugiyama, I. Ieiri, Hiroshi Suzuki, 2004, Pharmacogenetics.

SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers

K. Maeda, H. Kusuhara, Y. Sugiyama, 2007, Clinical pharmacology and therapeutics.

CYP2C19 polymorphism effect on phenobarbitone

E. Yukawa, S. Higuchi, N. Tashiro, 2000, European Journal of Clinical Pharmacology.

Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics

E. Yukawa, S. Higuchi, N. Tashiro, 2000 .

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy

S. Higuchi, H. Takane, I. Ieiri, 2009, Cancer Chemotherapy and Pharmacology.

Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.

E. Shimizu, N. Burioka, Y. Fukuoka, 2007, Therapeutic drug monitoring.

Effects of multiple‐dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers

N. Yasui-Furukori, M. Miura, I. Ieiri, 2015, Journal of clinical pharmacy and therapeutics.

Genetic Polymorphisms of Hepatic ABC-Transporter in Patients with Hepatocellular Carcinoma

M. Fukuda, I. Ieiri, A. Ohnishi, 2010 .

Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study

Y. Kumagai, I. Ieiri, T. Imai, 2019, Journal of clinical pharmacology.

The Antiplatelet Aggregation Effects of Aspirin Suppositories

K. Nakashima, I. Ieiri, K. Otsubo, 2003, Cerebrovascular Diseases.

The Use of Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation in Anti-Osteoporotic Drug Development: A Perspective

I. Ieiri, Chihiro Hasegawa, T. Ohno, 2014 .

A Multicenter, Randomized, Placebo-Controlled Phase I Investigator-Initiated Trial for Intravenous Administration of Pitavastatin-Loaded PLGA Nanoparticles (NK-104-NP) in Healthy Japanese Male Subjects

K. Egashira, I. Ieiri, T. Matoba, 2018 .

Safety, Tolerability, and Pharmacokinetics of NK-104-NP.

K. Egashira, I. Ieiri, T. Matoba, 2018, International heart journal.

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.

S. Higuchi, N. Tashiro, I. Ieiri, 2000, Therapeutic drug monitoring.

Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice

T. Kinoshita, S. Higuchi, H. To, 2009 .

Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis

I. Ieiri, Takeshi Hirota, Yushi Kashihara, 2018, British journal of clinical pharmacology.

Contribution of Angiotensin Converting Enzyme Gene Polymorphism to the Action of Angiotensin II Receptor Antagonist (CS-866)

T. Ogihara, S. Higuchi, M. Okada, 2002 .

Population pharmacokinetic–pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer

Y. Nakanishi, K. Takayama, I. Ieiri, 2016, Cancer Chemotherapy and Pharmacology.

Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2016, Drug Metabolism and Disposition.

Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.

K. Maeda, H. Kusuhara, Y. Sugiyama, 2019, Drug metabolism and pharmacokinetics.

Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2

Y. Sugiyama, S. Ozawa, J. Sawada, 2004, Pharmaceutical Research.

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

H. Kusuhara, Y. Sugiyama, S. Higuchi, 2008, Journal of Human Genetics.

Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2012, Journal of clinical pharmacology.

Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.

K. Maeda, H. Kusuhara, Y. Sugiyama, 2017, Journal of pharmaceutical sciences.

Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.

Yuichi Sugiyama, Hiroshi Ito, Akihiro Takano, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.

J. Kigawa, Y. Kanamori, Masakuni Takahashi, 2001, The Journal of pharmacology and experimental therapeutics.

Elucidation of N1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters

K. Maeda, H. Kusuhara, Y. Kato, 2019, Drug Metabolism and Disposition.

Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2011, Pharmacogenetics and genomics.

Nucleosome Positioning and Gene Regulation of the SGLT2 Gene in the Renal Proximal Tubular Epithelial Cells

I. Ieiri, Takeshi Hirota, Hiroaki Takesue, 2018, Molecular Pharmacology.

SNP Communication Novel Large-scale Deletion ( whole Exon 7 ) in the ABCC 2 Gene in a Patient with the Dubin-Johnson Syndrome

M. Mori, K. Kashiwabara, Y. Yata, 2009 .

Novel large-scale deletion (whole exon 7) in the ABCC2 gene in a patient with the Dubin-Johnson syndrome.

M. Mori, K. Kashiwabara, Y. Yata, 2009, Drug metabolism and pharmacokinetics.

Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method

Y. Hayashizaki, K. Maeda, Y. Sugiyama, 2013, The AAPS Journal.

Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.

Y. Sugiyama, S. Higuchi, H. Takane, 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

Methotrexate Chronotherapy is Effective Against Rheumatoid Arthritis

H. Sasaki, K. Eguchi, S. Higuchi, 2011, Chronobiology international.

Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer

Masafumi Nakamura, I. Ieiri, Toshikazu Tsuji, 2020, The Annals of pharmacotherapy.

Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy

Y. Nakanishi, I. Okamoto, I. Ieiri, 2021, Scientific Reports.

Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma

T. Yoshizumi, S. Masuda, S. Itoh, 2020, Cancer Chemotherapy and Pharmacology.

Characterization of ADME gene variation in 21 populations by exome sequencing

A. S. Gross, G. Abecasis, M. Nelson, 2016, Pharmacogenetics and genomics.

Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin’s Lymphoma Receiving ESHAP±R Therapy

K. Akashi, T. Miyamoto, I. Ieiri, 2022, AntiCancer Research.

Evaluation of Medication Instruction Sheets for Patients Undergoing R-CHOP Therapy in Non-Hodgkin’s Lymphoma

K. Akashi, T. Miyamoto, I. Ieiri, 2022, In Vivo.

Identification and Functional Characterization of Novel Nonsynonymous Variants in the Human Multidrug and Toxin Extrusion 2K

I. Ieiri, Takeshi Hirota, Hiroaki Takesue, 2014 .

Identification and Functional Characterization of Novel Nonsynonymous Variants in the Human Multidrug and Toxin Extrusion 2-K

I. Ieiri, Takeshi Hirota, Hiroaki Takesue, 2014, Drug Metabolism and Disposition.

Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues.

Eiji Shimizu, Kenji Otsubo, Hiroshige Nakamura, 2012, Lung cancer.

Dosing time-dependency of the arthritis-inhibiting effect of tacrolimus in mice.

S. Higuchi, H. To, I. Ieiri, 2011, Journal of pharmacological sciences.

Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.

I. Ieiri, S. Matsubayashi, Takeshi Hirota, 2016, Journal of diabetes and its complications.

Relationship between DNA Methylation in the 5′ CpG Island of the SLC47A1 (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver

Toshihiro Tanaka, I. Ieiri, Takeshi Hirota, 2018, Molecular Pharmacology.

[Pharmacokinetics and pharmacodynamics of anti-diabetic drugs--from the viewpoints of drug transporters and metabolic enzymes].

I. Ieiri, 2015, Nihon rinsho. Japanese journal of clinical medicine.

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects

S. Higuchi, I. Ieiri, A. Urae, 1996 .

Effects of the Serotonin 1A, 2A, 2C, 3A, and 3B and Serotonin Transporter Gene Polymorphisms on the Occurrence of Paroxetine Discontinuation Syndrome

Susumu Koyama, I. Ieiri, K. Mine, 2010, Journal of clinical psychopharmacology.

Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea.

N. Kinukawa, Y. Sawada, Misuzu Tanaka, 2008, The international journal of neuropsychopharmacology.

Influences of Artificial Heart-Lung Machine Operation on the Binding Sites of Albumin: Possibility of an Effective Administration Plan

S. Higuchi, I. Ieiri, K. Kawai, 2014, International Journal of Artificial Organs.

Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals

H. Takane, I. Ieiri, Takeshi Hirota, 2018, Journal of clinical pharmacology.

Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report

I. Ieiri, H. Tateishi, Daisuke Miyazu, 2021, Journal of pharmaceutical health care and sciences.

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

T. Kubota, S. Higuchi, K. Chiba, 2000, European Journal of Clinical Pharmacology.

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114

I. Ieiri, T. Takenaka, K. Yoshisue, 2021, CPT: pharmacometrics & systems pharmacology.

Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.

S. Higuchi, I. Ieiri, A. Suzuki, 2001, Pharmacogenetics.

Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy.

E. Shimizu, A. Yamasaki, S. Higuchi, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study.

I. Ieiri, Y. Kurata, Takeshi Hirota, 2021, Drug metabolism and pharmacokinetics.

Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.

S. Higuchi, I. Ieiri, Daisuke Kobayashi, 2011, Drug metabolism and pharmacokinetics.

The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats.

I. Ieiri, R. Fu, Soichiro Tajima, 2021, Life sciences.

Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis.

S. Masuda, I. Ieiri, R. Fu, 2021, Toxicology letters.

Analysis of the thinking process of pharmacists in response to changes in the dispensing environment using the eye-tracking method

I. Ieiri, Toshikazu Tsuji, Takeshi Hirota, 2022, Journal of pharmaceutical health care and sciences.

Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide.

K. Maeda, H. Kusuhara, T. Mizuno, 2017, Journal of pharmaceutical sciences.

Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Child–Pugh and MELD scores

I. Ieiri, Y. Kurata, Takeshi Hirota, 2022, British journal of clinical pharmacology.

Differences in Theophylline Clearance between Patients with Chronic Hepatitis and those with Liver Cirrhosis.

I. Ieiri, Y. Kurata, H. Araki, 2020, Therapeutic drug monitoring.

Identification of drug transporters contributing to oxaliplatin‐induced peripheral neuropathy

I. Ieiri, Takeshi Hirota, Shunsuke Fujita, 2018, Journal of neurochemistry.

Association Between Immune-Related Hypothyroidism and Survival Outcomes in Patients with Head and Neck Cancer Treated with Nivolumab

R. Yasumatsu, I. Ieiri, M. Ikebe, 2021 .

Modeling and simulation of bone mineral density response from a phase 2 study of ONO‐5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis

I. Ieiri, H. Kastrissios, J. Monteleone, 2014, Journal of clinical pharmacology.

Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO‐5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females

I. Ieiri, Chihiro Hasegawa, T. Ohno, 2014, Journal of clinical pharmacology.

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406

I. Ieiri, Takeshi Hirota, K. Suetsugu, 2022, Clinical Pharmacokinetics.

Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study

K. Harada, J. Imamura, T. Kamisawa, 2022, EBioMedicine.

Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5'-upstream regulatory region.

I. Ieiri, K. Otsubo, Takeshi Hirota, 2011, Journal of pharmaceutical sciences.

The association of tobacco use with prescription of muscle relaxants, benzodiazepines, and opioid analgesics for non‐cancer pain

A. Hagihara, D. Onozuka, I. Ieiri, 2019, The American journal on addictions.

Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis.

Y. Oida, K. Kitaichi, I. Ieiri, 2022, Drug metabolism and pharmacokinetics.

Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain.

T. Morioka, I. Ieiri, Y. Ishii, 2003, The Journal of toxicological sciences.

Telmisartan and N-acetylcysteine Suppress Group V Secretory Phospholipase A2 Expression in TNF&agr;-stimulated Human Endothelial Cells and Reduce Associated Atherogenicity

T. Kitazono, S. Ohdo, K. Sonoki, 2012, Journal of cardiovascular pharmacology.

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status

T. Ishizaki, I. Ieiri, A. Urae, 2005, Pharmacogenetics and genomics.

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

T. Ishizaki, I. Ieiri, K. Nakagawa, 2001, European Journal of Clinical Pharmacology.

P-Hydroxylation of Phenobarbital: Relationship to (s)-Mephenytoin Hydroxylation (CYP2C19) Polymorphism

S. Higuchi, N. Tashiro, I. Ieiri, 2001, Therapeutic drug monitoring.

CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.

E. Yukawa, S. Higuchi, N. Tashiro, 2000, European journal of clinical pharmacology.

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.

S. Higuchi, I. Ieiri, A. Urae, 1998, Therapeutic drug monitoring.

The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.

I. Tamai, M. Miura, I. Ieiri, 2015, Drug metabolism and pharmacokinetics.

Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers

H. Kusuhara, I. Tamai, M. Miura, 2014, European Journal of Clinical Pharmacology.

Phenytoin intoxication induced by fluvoxamine.

E. Yukawa, S. Higuchi, N. Tashiro, 2001, Therapeutic drug monitoring.

Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation

T. Kubota, I. Ieiri, S. Irie, 2018, European Journal of Clinical Pharmacology.

FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA

M. Oshimura, Y. Sugiyama, J. Kigawa, 2005, Drug Metabolism and Disposition.

Population Pharmacokinetic and Pharmacodynamic Analysis of Linezolid and a Hematologic Side Effect, Thrombocytopenia, in Japanese Patients

S. Higuchi, H. Takane, I. Ieiri, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP

K. Maeda, H. Kusuhara, Y. Sugiyama, 2012, British journal of pharmacology.

Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).

I. Ieiri, 2012, Drug metabolism and pharmacokinetics.

Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status.

M. Oshimura, E. Nanba, S. Higuchi, 2004, Human molecular genetics.

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Y. Nakanishi, K. Takayama, I. Okamoto, 2014, Cancer Chemotherapy and Pharmacology.

Relationship between DNA Methylation in the 5′ CpG Island of the SLC47A1 (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver

Toshihiro Tanaka, I. Ieiri, Takeshi Hirota, 2018, Molecular Pharmacology.

Relationship between DNA Methylation in the 59 CpG Island of the SLC47A1 (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver s

Toshihiro Tanaka, I. Ieiri, Takeshi Hirota, 2017 .

Pharmacokinetic Study of Zonisamide in Patients Undergoing Brain Surgery

T. Morioka, S. Nishio, M. Fukui, 1996, The Journal of pharmacy and pharmacology.

Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay.

I. Ieiri, K. Otsubo, H. Shuto, 1996, Therapeutic drug monitoring.

Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment

Youngjo Lee, Y. Sugiyama, Joo-Youn Cho, 2014, Pharmacogenetics and genomics.

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid &bgr; Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

E. Siemers, R. Dean, S. Friedrich, 2012, Clinical neuropharmacology.

MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells

I. Ieiri, Takeshi Hirota, Nozomi Matsumoto, 2013, BMC Cancer.

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

Yuichi Sugiyama, Miyuki Kimura, Hiroyuki Kusuhara, 2008, Clinical pharmacology and therapeutics.

Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes.

K. Ohashi, I. Ieiri, Takeshi Hirota, 2013, Drug metabolism and pharmacokinetics.

Association between DNA Methylation in the miR-328 5’-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta

H. Takane, I. Ieiri, Daisuke Kobayashi, 2013, PloS one.

Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions.

Misaki Suzuki, Ichiro Ieiri, Katsuomi Ichikawa, 2013, Pharmacogenomics.

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

Miyuki Kimura, Kenji Otsubo, Shun Higuchi, 2002, Clinical pharmacology and therapeutics.

Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure

Y. Sugiyama, A. Shinagawa, S. Tokuhiro, 2012, Journal of Human Genetics.

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

Y. Sugiyama, S. Higuchi, I. Ieiri, 2009, Expert opinion on drug metabolism & toxicology.

Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

Yuichi Sugiyama, Miyuki Kimura, Kenji Otsubo, 2003, Clinical pharmacology and therapeutics.

The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications

H. Takane, I. Ieiri, K. Otsubo, 2004, Clinical pharmacokinetics.

Haplotype-Oriented Genetic Analysis and Functional Assessment of Promoter Variants in the MDR1 (ABCB1) Gene

J. Kigawa, N. Terakawa, H. Takane, 2004, Journal of Pharmacology and Experimental Therapeutics.

Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene

Keizo Sugimachi, Kenji Otsubo, Atsushi Yamauchi, 2002, Transplantation.

Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients

Hiroyasu Ito, M. Takemura, M. Seishima, 2010, The Journal of pharmacy and pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma

I. Ieiri, Takeshi Higuchi, Tsuyoshi Kaneko, 2018, Journal of clinical pharmacology.

Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity.

Shota Yamamoto, I. Ieiri, Wei Zhang, 2022, Toxicology and applied pharmacology.

ANALYSIS OF THE FACTORS INFLUENCING ANTI‐EPILEPTIC DRUG CONCENTRATIONS‐CARBAMAZEPINE

I. Ieiri, T. Aoyama, S. Higuchi, 1990, Journal of clinical pharmacy and therapeutics.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

M. Ritchie, I. Ieiri, H. Echizen, 2006, Pharmacogenetics and genomics.

The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics

E. Yukawa, S. Higuchi, N. Tashiro, 1998, Epilepsia.

Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.

S. Higuchi, N. Tashiro, I. Ieiri, 1997, British journal of clinical pharmacology.

Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene

I. Ieiri, Daisuke Kobayashi, Takeshi Hirota, 2018, Drug Metabolism and Disposition.

Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals

K. Maeda, H. Kusuhara, Y. Sugiyama, 2012, Pharmacogenetics & Genomics.

Inter-individual Differences in the Expression of ABC and SLC Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 (MRP3) Gene

I. Ieiri, Takeshi Hirota, Daisuke, 2018 .

Neonatal Dubin–Johnson syndrome: Novel compound heterozygous mutation in the ABCC2 gene

T. Kusaka, S. Itoh, H. Okada, 2014, Pediatrics international : official journal of the Japan Pediatric Society.

Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin

H. Takane, I. Ieiri, C. Shigemasa, 2006, Journal of Human Genetics.

Rifampin reduces the analgesic effect of transdermal fentanyl

H. Takane, I. Ieiri, K. Hosokawa, 2005, The Annals of pharmacotherapy.

Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.

K. Akashi, Y. Mori, I. Ieiri, 2023, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study

S. Higuchi, I. Ieiri, K. Ohtsubo, 1995, European Journal of Clinical Pharmacology.

Pharmacoepidemiological study on adverse reactions of antiepileptic drugs.

S. Higuchi, I. Ieiri, T. Aoyama, 1992, Chemical & pharmaceutical bulletin.

Development and Validation of A Liquid Chromatography–Tandem Mass Spectrometry Method to Simultaneously Measure Tacrolimus and Everolimus Concentrations in Kidney Allograft Biopsies After Kidney Transplantation

K. Kaku, Y. Okabe, H. Noguchi, 2021, Therapeutic drug monitoring.

Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models.

I. Ieiri, Takeshi Hirota, Yushi Kashihara, 2018, Drug metabolism and pharmacokinetics.

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study

K. Akashi, T. Miyamoto, Y. Mori, 2021, Drugs in R&D.

Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.

S. Higuchi, I. Ieiri, A. Urae, 1999, British journal of clinical pharmacology.

Elucidation of N 1 -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters s

K. Maeda, H. Kusuhara, Y. Kato, 2019 .

Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information

S. Ohga, I. Ieiri, T. Fukuda, 2021, Therapeutic drug monitoring.

Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.

Ichiro Ieiri, I. Ieiri, Takeshi Hirota, 2013, Drug metabolism and pharmacokinetics.

Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia

I. Ieiri, Koji Kato, N. Egashira, 2023, In Vivo.

Therapeutic Drug Monitoring Services at Kyushu University Hospital in Japan

E. Yukawa, I. Ieiri, K. Ohtsubo, 1990, DICP : the annals of pharmacotherapy.

Genetic polymorphisms and functional characterization of the 5′‐flanking region of the human CYP2C9 gene: In vitro and in vivo studies

S. Higuchi, N. Tashiro, I. Ieiri, 2001, Clinical pharmacology and therapeutics.

Drug–drug interactions that interfere with statin metabolism

I. Ieiri, Takeshi Hirota, 2015, Expert opinion on drug metabolism & toxicology.

Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

S. Higuchi, A. Sarashina, I. Ieiri, 2010, British journal of clinical pharmacology.

The relationship between fine particulate matter (PM2.5) and schizophrenia severity

A. Hagihara, D. Onozuka, I. Ieiri, 2018, International Archives of Occupational and Environmental Health.

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.

I. Ieiri, Kazuko Inoue, E. Shikata, 2003, Blood.

Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.

S. Higuchi, N. Tashiro, I. Ieiri, 2000, Therapeutic drug monitoring.

Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records.

H. Shimomura, I. Ieiri, S. Matsubayashi, 2014, British journal of clinical pharmacology.

Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

I. Ieiri, Takeshi Hirota, Shota Muraki, 2018, Clinical Pharmacokinetics.

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study

K. Harada, J. Imamura, A. Tanaka, 2022, BMJ open gastroenterology.

Psychotropic Drug–Drug Interactions Involving P-Glycoprotein

N. Yasui-Furukori, I. Ieiri, Y. Akamine, 2012, CNS Drugs.

Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms

Kazuya Maeda, Yuichi Sugiyama, Shun Higuchi, 2009, Journal of clinical pharmacology.

Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril

K. Maeda, H. Kusuhara, Y. Sugiyama, 2006, Clinical pharmacology and therapeutics.

An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins

I. Ieiri, Takeshi Hirota, Yuito Fujita, 2020, Expert opinion on drug metabolism & toxicology.

Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.

K. Maeda, H. Kusuhara, Y. Sugiyama, 2019, Drug metabolism and pharmacokinetics.

Predictive Performance of Bayesian Method in a Simulation Work: One-Compartment Open Linear Model Containing an Oral Route

Toshinobu Aoyama, Shun Higuchi, Ichiro Ieiri, 1988 .

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.

I. Ieiri, H. Echizen, G. Wilkinson, 2004, Blood.

Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.

E. Nanba, S. Higuchi, Y. Fukumaki, 2000, Pharmacogenetics.

Direct and Rapid Genotyping of Glutathione-S-transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 Method

Y. Hayashizaki, H. Kusuhara, Y. Sugiyama, 2010, Drug Metabolism and Disposition.

Microsoft Word-53165249-file00

Y. Hayashizaki, H. Kusuhara, Y. Sugiyama, 2010 .

Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p‐Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2013, Journal of clinical pharmacology.

Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'-flanking Region on OCT3 Expression and Sebum Levels in Human Skin.

M. Furue, T. Nakahara, I. Ieiri, 2020, Journal of dermatological science.

Population pharmacokinetic analysis of phenytoin after intravenous administration of fosphenytoin in adult and elderly epileptic patients.

I. Ieiri, Takeshi Hirota, Yushi Kashihara, 2019, Therapeutic drug monitoring.

ANALYSIS OF THE FACTORS INFLUENCING ANTI‐EPILEPTIC DRUG CONCENTRATIONS‐VALPROIC ACID

S. Higuchi, I. Ieiri, T. Aoyama, 1990, Journal of clinical pharmacy and therapeutics.

Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes

I. Ieiri, Takeshi Hirota, Satoshi Nakao, 2023, International Journal of Clinical Oncology.

Influence of Additional Therapy with Zonisamide (Excegran) on Protein Binding and Metabolism of Carbamazepine

S. Higuchi, I. Ieiri, K. Ohtsubo, 1994, Epilepsia.

Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.

Shun Higuchi, Hiroko Tabuchi, Ichiro Ieiri, 2009, Pharmacogenomics.

Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis

Jann-Yuan Wang, Ming-Chia Lee, I. Ieiri, 2022, British journal of clinical pharmacology.

Effect of Curcumin on Sulfasalazine Pharmacokinetics in Healthy Volunteers

I. Ieiri, S. Irie, Takeshi Hirota, 2016 .

Effect of Food Thickener and Deglutition Aid Jelly on Pharmacokinetics of Drugs

H. Takane, I. Ieiri, K. Otsubo, 2011 .

Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing.

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2012, International journal of clinical pharmacology and therapeutics.

Polymorphism in human organic cation transporters and metformin action.

S. Higuchi, H. Takane, I. Ieiri, 2008, Pharmacogenomics.

Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method

Y. Hayashizaki, K. Maeda, Y. Sugiyama, 2013, The AAPS Journal.

Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial.

H. Lenz, R. Mayer, A. Ohtsu, 2015 .

Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines

I. Ieiri, Mariko Deguchi, S. Irie, 2016, Scientific Reports.

Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms.

S. Higuchi, H. Takane, I. Ieiri, 2008, Current drug metabolism.

Apple juice greatly reduces systemic exposure to atenolol.

K. Ohashi, Joo-Youn Cho, K. Yu, 2013, British journal of clinical pharmacology.

Acute Hypotension after Loxoprofen Sodium Co-administration in Two Acute Myeloid Leukemia Patients Undergoing Chemotherapy Treatment.

I. Ieiri, K. Otsubo, K. Ishiga, 2003 .

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.

S. Higuchi, I. Ieiri, A. Urae, 1996, Clinical pharmacology and therapeutics.

Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine–alprazolam interaction in patients with psychosomatic disease

Y. Sawada, I. Ieiri, K. Mine, 2009, European Journal of Clinical Pharmacology.

A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.

S. Higuchi, N. Tashiro, I. Ieiri, 2004, Pharmacopsychiatry.

Detection of overdose and underdose prescriptions—An unsupervised machine learning approach

I. Ieiri, Toshikazu Tsuji, N. Egashira, 2021, PloS one.

I. Ieiri, H. Takaki, Erina Kaneko, 2022, Journal of Pharmaceutical Health Services Research.

Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers

H. Kusuhara, I. Tamai, M. Miura, 2014, European Journal of Clinical Pharmacology.

Development of Real-world Data-based Medication Instruction Sheet for Acute Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy

I. Ieiri, Koji Kato, N. Egashira, 2023, AntiCancer Research.

Regulation of Organic Anion Transporting Polypeptide 2B1 Expression by MicroRNA in the Human Liver.

I. Ieiri, Takeshi Hirota, S. Kawano, 2020, Molecular pharmaceutics.

Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation–Positive Acute Myelogenous Leukemia

K. Akashi, T. Miyamoto, I. Ieiri, 2022, Therapeutic drug monitoring.

Psychological assessment of acute schizophrenia patients who experienced seclusion either alone or in combination with restraint

A. Hagihara, D. Onozuka, I. Ieiri, 2018, International journal of psychiatry in medicine.

Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding

S. Higuchi, I. Ieiri, K. Ohtsubo, 1995, Brain and Development.

Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene

I. Ieiri, Takeshi Hirota, Masato Fukae, 2015, British journal of clinical pharmacology.

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Y. Nakanishi, K. Takayama, I. Okamoto, 2014, Cancer Chemotherapy and Pharmacology.

Profiles and Outcomes of Skin Injuries Caused by Injectable Drug Extravasation

I. Ieiri, M. Iwata, Satoshi Nakao, 2023, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide

I. Ieiri, Soichiro Ito, Takeshi Hirota, 2021, Genes.

Simultaneous determination of carbamate pesticides in human serum and urine by automatic reversed-phase HPLC combined with on-line column enrichment

I. Ieiri, K. Otsubo, Y. Fujii, 2004 .

Elucidation of N 1 -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters s

K. Maeda, H. Kusuhara, Y. Kato, 2019 .

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

H. Kusuhara, Y. Sugiyama, J. Ware, 2008, Clinical pharmacology and therapeutics.

Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system

I. Ieiri, Satoshi Nakao, M. Masuta, 2023, Heliyon.

Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation

T. Kubota, I. Ieiri, S. Irie, 2018, European Journal of Clinical Pharmacology.

Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.

I. Ieiri, Takeshi Hirota, Shunsuke Eguchi, 2013, Drug Metabolism and Pharmacokinetics.

Interindividual variability in statin pharmacokinetics and effects of drug transporters.

I. Ieiri, Takeshi Hirota, 2024, Expert opinion on drug metabolism & toxicology.

Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information

K. Maeda, H. Kusuhara, Y. Sugiyama, 2016, Drug Metabolism And Disposition.